These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
767 related articles for article (PubMed ID: 17916095)
1. The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions. Shield PW; Koivurinne K Cytopathology; 2008 Aug; 19(4):218-23. PubMed ID: 17916095 [TBL] [Abstract][Full Text] [Related]
2. The diagnostic utility of D2-40, calretinin, CK5/6, desmin and MOC-31 in the differentiation of mesothelioma from adenocarcinoma in pleural effusion cytology. Hyun TS; Barnes M; Tabatabai ZL Acta Cytol; 2012; 56(5):527-32. PubMed ID: 23075894 [TBL] [Abstract][Full Text] [Related]
3. [Significance of combining detection of E-cadherin, carcinoembryonic antigen, and calretinin in cytological differential diagnosis of serous effusion]. Su XY; Li GD; Liu HB; Jiang LL Ai Zheng; 2004 Oct; 23(10):1185-9. PubMed ID: 15473932 [TBL] [Abstract][Full Text] [Related]
4. The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement. Saad RS; Lindner JL; Lin X; Liu YL; Silverman JF Diagn Cytopathol; 2006 Dec; 34(12):801-6. PubMed ID: 17115439 [TBL] [Abstract][Full Text] [Related]
5. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Cury PM; Butcher DN; Fisher C; Corrin B; Nicholson AG Mod Pathol; 2000 Feb; 13(2):107-12. PubMed ID: 10697265 [TBL] [Abstract][Full Text] [Related]
6. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation]. Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913 [TBL] [Abstract][Full Text] [Related]
7. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Comin CE; Novelli L; Boddi V; Paglierani M; Dini S Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372 [TBL] [Abstract][Full Text] [Related]
8. Immunocytochemical panel for distinguishing between adenocarcinomas and reactive mesothelial cells in effusion cell blocks. Kim JH; Kim GE; Choi YD; Lee JS; Lee JH; Nam JH; Choi C Diagn Cytopathol; 2009 Apr; 37(4):258-61. PubMed ID: 19217030 [TBL] [Abstract][Full Text] [Related]
9. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions. Friedman MT; Gentile P; Tarectecan A; Fuchs A Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609 [TBL] [Abstract][Full Text] [Related]
11. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma. Ordóñez NG Mod Pathol; 1998 Oct; 11(10):929-33. PubMed ID: 9796717 [TBL] [Abstract][Full Text] [Related]
12. Glyco- and immunohistochemical refinement of the differential diagnosis between mesothelioma and metastatic carcinoma and survival analysis of patients. Kayser K; Böhm G; Blum S; Beyer M; Zink S; André S; Gabius HJ J Pathol; 2001 Feb; 193(2):175-80. PubMed ID: 11180163 [TBL] [Abstract][Full Text] [Related]
13. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. Comin CE; Saieva C; Messerini L Am J Surg Pathol; 2007 Aug; 31(8):1139-48. PubMed ID: 17667535 [TBL] [Abstract][Full Text] [Related]
14. WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions. Zhu W; Michael CW Diagn Cytopathol; 2007 Jun; 35(6):370-5. PubMed ID: 17497661 [TBL] [Abstract][Full Text] [Related]
15. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids. Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338 [TBL] [Abstract][Full Text] [Related]
16. Podoplanin is a better immunohistochemical marker for sarcomatoid mesothelioma than calretinin. Padgett DM; Cathro HP; Wick MR; Mills SE Am J Surg Pathol; 2008 Jan; 32(1):123-7. PubMed ID: 18162779 [TBL] [Abstract][Full Text] [Related]
17. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization. Afify AM; Stern R; Michael CW Diagn Cytopathol; 2005 Mar; 32(3):145-50. PubMed ID: 15690337 [TBL] [Abstract][Full Text] [Related]
18. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry. Su XY; Li GD; Liu WP; Xie B; Jiang YH Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004 [TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma. Kushitani K; Takeshima Y; Amatya VJ; Furonaka O; Sakatani A; Inai K Pathol Int; 2007 Apr; 57(4):190-9. PubMed ID: 17316414 [TBL] [Abstract][Full Text] [Related]
20. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions. Bassarova AV; Nesland JM; Davidson B Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]